Patents by Inventor Jack Singer

Jack Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8748577
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: June 10, 2014
    Assignee: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Publication number: 20120252717
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Application
    Filed: January 31, 2012
    Publication date: October 4, 2012
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Patent number: 8129348
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Grant
    Filed: October 14, 2008
    Date of Patent: March 6, 2012
    Assignee: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Publication number: 20090298762
    Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.
    Type: Application
    Filed: October 14, 2008
    Publication date: December 3, 2009
    Applicant: Cell Therapeutics, Inc.
    Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
  • Publication number: 20070167349
    Abstract: Disclosed are methods for selecting a treatment for, and then treating various types of cancers in males and females, comprising delivery of an anti-cancer drug conjugated to a poly (amino acid) polymer, optionally in combination with estrogen therapy.
    Type: Application
    Filed: December 5, 2006
    Publication date: July 19, 2007
    Applicant: Cell Therapeutics, Inc.
    Inventor: Jack Singer
  • Publication number: 20050148600
    Abstract: Methods are provided for treating or preventing obesity by inhibiting the activity of lysophosphatidic acyltransferase ? (LPAAT-?).
    Type: Application
    Filed: August 25, 2004
    Publication date: July 7, 2005
    Inventor: Jack Singer
  • Publication number: 20030033011
    Abstract: An intraocular lens (IOL) corrects vision disorders and prevents the formation of cataracts. The IOL can be inserted in the anterior or posterior chamber of the eye, or can be iris-fixated. The IOL can correct for myopia, hyperopia, presbyopia and/or astigmatism. Additionally, the IOL contains an ultraviolet radiation (UVR) blocker, that absorbs UVR in the 300-400 nm range. The absorption of the UVR allows the IOL to reduce or eliminate cataract formation.
    Type: Application
    Filed: August 8, 2001
    Publication date: February 13, 2003
    Inventors: Jack A. Singer, Joe Kiernan
  • Patent number: 5965564
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: March 20, 1998
    Date of Patent: October 12, 1999
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5792772
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: August 11, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5739138
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 14, 1998
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5652243
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: July 29, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Jack Singer
  • Patent number: 5648357
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: September 16, 1994
    Date of Patent: July 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5629315
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: May 13, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5620984
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating inflammatory disease.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5621102
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: April 15, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5612349
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: March 18, 1997
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5580873
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating proliferative vascular disease.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 3, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5580874
    Abstract: Them is disclosed compounds and pharmaceutical compositions that is R enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating the side effects of immunosuppressive agent and interleukin-2 therapy.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: December 3, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 5567704
    Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating baldness.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: October 22, 1996
    Assignee: Cell Therapeutics, Inc.
    Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
  • Patent number: 4593031
    Abstract: This invention relates to a composition and method for potentiating the antidepressant effect of dibenzocycloheptadiene-type antidepressant agents, for example, nortriptyline, in the treatment of depression, especially geriatric depression, by administering them in combination with an approximately 1:1:1 by weight mixture of dihydroergocryptine (2:1 .alpha.:.beta.), dihydroergocornine and dihydroergocristine.
    Type: Grant
    Filed: June 5, 1985
    Date of Patent: June 3, 1986
    Assignee: Sandoz, Inc.
    Inventors: Robert W. Griffith, Jack Singer